Hushan Yuan, Moses Q Wilks, Marc D Normandin, Georges El Fakhri, Charalambos Kaittanis and Lee Josephson
Harvard Medical School, USA
Posters & Accepted Abstracts: J Nucl Med Radiat Ther
Heat Induced Radiolabeling (HIR) of Feraheme (FH) nanoparticles (NP) is a chelator free, radiocation surface adsorption (RSA) method using heat (120�°C) to bond cations to the iron oxide core of FHNP in less than 3 hours. It repurposes the FHNP from its current uses of iron anemia treatment (approved indication) and MR contrast agent (off-label use) to a radiolabeled PET or SPECT agent, allowing experience with a well-established drug to suggest the safety, pharmacokinetics and clinical applications of new, radiolabeled NPs. HIR differs from other RSA methods in its (i) radiocation flexibility by using any of three cations widely employed in clinical imaging (89Zr4+ or 64Cu2+ for PET and 111In3+ for SPECT), (ii) procedural simplicity: bonding radiocations to a NP drug with heat, (iii) leaving the physical and biological properties of the NP drug unchanged, save for the presence of trace amounts of radiocation and, (iv) ability to generate multivalency of surface targeting groups since azideâ��s survival of HIR conditions. When injected, HIR FHNPs can be internalized by circulating monocytes that traffic to normal lymph nodes and abnormal sites of inflammation. In addition, many bioactive molecules called targeting groups (such as folate, cRGD, protamine, etc.) can be attached to the HIR-FHNPs through click chemistry and their bioactivities are well retained for receptor targeting, which grants HIR FHNPs potentials for active targeting drug delivery and cell labeling. The combination of HIR and targeting group attachments provides a multi-radiocation RSA method for multimodal molecular imaging as well as for targeting radiation therapy.
Email: hyuan@mgh.harvard.edu
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 